12 results about "Biguanide" patented technology

This invention discloses a layer-by-layer deposition modified ultrafiltration membrane with both antifouling and antibacterial properties, its preparation method, and its applications. Through layer-by-layer assembly technology, a tannic acid (TA) anion layer and a polyhexamethylene biguanide (PHMB) cation layer are alternately deposited on the surface of an ultrafiltration membrane. Under weakly alkaline conditions, electrostatic interactions, hydrogen bonding, Schiff base reactions, and Michael addition reactions are simultaneously utilized to achieve both non-covalent and covalent bonding, constructing a stable and dense integrated antibacterial-antifouling composite coating. This coating has a contact-type antibacterial structure, which can effectively kill bacteria in water and inhibit biofilm formation at the source. Simultaneously, it significantly improves the hydrophilicity of the membrane surface, reduces pollutant adsorption and deposition, and achieves synergistic enhancement of antibacterial and antifouling properties. The preparation process of this invention is mild, simple, low-cost, and environmentally friendly. The modified membrane exhibits high flux retention, excellent separation performance, and excellent operational stability, and can be widely applied in water treatment scenarios such as municipal wastewater treatment.

An ophthalmic composition according to the present invention contains (A) 0.01-0.5 w / w% of a copolymer having constituent units represented by formula (1a) to formula (1c), where the molar ratio of each constituent unit is a:b:c=100:10-400:2-50 and the weight average molecular weight is 5,000-2,000,000, (B) 0.000001-0.0001 w / w% of polyhexamethylene biguanide represented by formula (2) or a salt thereof, and (C) 0.02-5.0 w / w% of polyoxyethylene hydrogenated castor oil and / or (D) 0.02-5.0 w / w% of polyoxyethylene glycol monostearate.　According to the present invention, it is possible to provide an ophthalmic composition that exhibits sufficient preservation efficacy and has high lubricity.

This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions in vitro and / or in vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing optionally wherein these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing are used in therapeutic regimens that further include the administration of other therapeutic agents, e.g., mitochondrial inhibitors and / or biguanides or small molecule MCT1 inhibitors.

The application provides a preparation method of indaziflam, which uses indamine and dicyandiamide as reactants, and magnesium-aluminum hydrotalcite as a catalyst to react in an organic solvent to obtain a biguanide intermediate, wherein the magnesium-aluminum hydrotalcite has a molar ratio of Mg / Al of 3:1-4:1 and is activated by calcination at 400-500 DEG C; and the biguanide intermediate is reacted with R-2-fluoropropyl methyl ester to generate indaziflam. The application uses the activated magnesium-aluminum hydrotalcite as a catalyst to prepare indaziflam, which can avoid the generation of aluminum-containing wastewater, the biguanide intermediate generated in the reaction has relatively stable properties, and the prepared indaziflam has relatively high purity and yield.

This invention discloses a skin repair dressing containing ectoine and its preparation method, relating to the field of skin care technology. By weight, it comprises the following components: ectoine: 2-5 parts, panthenol: 1-3 parts, sodium hyaluronate: 0.05-0.1 parts, glycerin: 5.0-8.0 parts, trehalose: 0.5-1.5 parts, squalane: 3.0-5.0 parts, caprylic / capric triglyceride: 4.0-6.0 parts, cetyl ethylhexanoate: 3.0-5.0 parts, Montanov L: 2.0-4.0 parts, carbomer: 0.1-0.3 parts, and p-hydroxyethylhexanoate. Acetophenone: 0.3-0.5 parts, 1,2-hexanediol: 0.8-1.2 parts, triethanolamine: 0.1-0.3 parts, polyhexamethylene biguanide (PHMB): 0.01-0.03 parts, ceramide: 0.05-0.1 parts, with purified water as the balance, and the total weight of all components is 100 parts. This invention combines active ingredients such as ectoine to repair the skin in multiple dimensions, is suitable for various skin types, and adds antibacterial ingredients to make the effect more lasting. Standardized preparation process is adopted to control the parameters of each step, ensuring uniform and stable dressing, ensuring hygiene and safety, and achieving stable product quality and consistent effect.

This disclosure relates to a composite membrane comprising a porous support structure, a polyethyleneimine (PEI) layer coated on the support structure, and polyhexamethylene biguanide (PHMB) grafted onto the coating of the support structure. This disclosure also provides a method for producing the composite membrane. This disclosure further provides a filtration and / or diffusion apparatus comprising the composite membrane.

This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.

This invention relates to a complex for mitigating the toxicity and amplifying the selectivity of cationic antibacterial agents, and its preparation method. It utilizes a stable complex formed by a cationic antibacterial agent (containing polyhexamethylene biguanide and an antimicrobial peptide mimic) and anionic polyelectrolytes, and employs this complex to mitigate the toxicity of the cationic antibacterial agent and amplify its antibacterial selectivity. This invention is applicable to multiple fields such as biomedicine, skin and mucous membrane care, antibacterial treatment of medical devices, and treatment of multidrug-resistant bacterial infections, and has broad industrialization prospects and clinical application value.

This invention discloses a compound, composition, and application for increasing the sensitivity of anti-liver cancer drugs. The compound is a biguanide compound with the following structural formula: R1 is a C4 saturated alkyl group, R2 is a para-substituted aromatic cyclic group, and the substituent is trifluoromethoxy. The composition comprises the above-mentioned biguanide compound and lenvatinib. The compound and composition of this application can improve the sensitivity of anti-liver cancer drugs and have a significant anti-liver cancer effect.

The application discloses an anti-HPV gel containing traditional Chinese medicine extracts, and raw material components include traditional Chinese medicine extracts, polyhexamethylene biguanide (PHMB), carbomer, glycerol, sodium hyaluronate, lactic acid and purified water; wherein the mass fraction of the polyhexamethylene biguanide (PHMB) is 0.11-0.13‰ (w / w). The anti-HPV gel containing traditional Chinese medicine extracts is characterized by multi-target point synergy, that is, traditional Chinese medicine anti-inflammatory repair and PHMB mild bacteriostasis; the gel is mild and safe, has a weak acid formula, is suitable for the physiological environment of a female reproductive tract, has no mucous membrane irritation, is convenient to use, has good adhesion, is easy to absorb and does not contaminate clothes.

This invention relates to the field of traditional Chinese medicine antibacterial liquid technology, and particularly to a traditional Chinese medicine antibacterial liquid for nasal use, made from the following raw materials: Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, Mentha haplocalyx, and polyhexamethylene biguanide. This invention combines nine traditional Chinese medicines—Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, and Mentha haplocalyx—with polyhexamethylene biguanide. The traditional Chinese medicine components are an improvement on the ancient formula of Xanthium sibiricum powder, synergistically exerting the effects of clearing the lungs and nasal passages, dispelling wind and cold, and anti-inflammatory and anti-allergic properties. Polyhexamethylene biguanide provides broad-spectrum antibacterial efficacy. By changing the traditional oral dosage form to a nasal drop, the liquid acts directly on the nasal mucosa lesion site, avoiding the first-pass effect of the liver and the metabolic burden on the kidneys associated with oral medications, significantly improving drug safety. Skin irritation, eye irritation, and allergy tests all showed no irritation or sensitization.

Provided are antimicrobial compositions and methods for depositing or coating an antimicrobial or antibacterial composition on a substrate to prevent microbial adhesion. The antimicrobial composition can include a cationic polymer having a polyallylamine backbone. A portion of the polyallylamine backbone can be functionalized to have at least one of a guanidine functional group and a biguanide functional group.